Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst
Congress of the International Society on Thrombosis and Haemostasis
SAN CARLOS, Calif., July 5 /PRNewswire-FirstCall/ --
Nuvelo,Inc. (Nasdaq: NUVO) today announced that data from the ANTHEM(Anticoagulation with rNAPc2 To Help Eliminate MACE)/TIMI 32 Phase2 trial looking at recombinant nematode anticoagulant protein c2(rNAPc2) in patients with acute coronary syndromes (ACS),preclinical data evaluating rNAPc2 in mouse models of colorectalcancer, and precli...
Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in
Journal of American College of Cardiology
SAN CARLOS, Calif., June 19, 2007 /PRNewswire-FirstCall/ --
Nuvelo, Inc. today announced the publication of the Phase 2proof-of-concept data from the Anthem (Anticoagulation with rNAPc2To Help Eliminate MACE)/TIMI 32 clinical trial (N=255) in the June26th issue of the Journal of of Cardiology (JACC), demonstratingthat higher-dose (greater than or equal to 7.5 mcg/kg) recombinantnematode a...
Nuvelo Announces Publication of Preclinical Study Results
Demonstrating the Potential of NTB-A as a New Target for Leukemia
and Lymphomas
SAN CARLOS, Calif., June 05, 2007 /PRNewswire-FirstCall/ --
Nuvelo, Inc. today announced the publication of data from apreclinical study of novel monoclonal antibodies against thecell-surface protein NTB-A. The data demonstrate that NTB-A is apotential new target for immunotherapy of B-cell malignanciesincluding leukemia and lymphomas. The study, entitled "The lymphoidcell surface recepto...
Nuvelo Announces Publication of NU206 Study Results in
Gastroenterology
SAN CARLOS, Calif, April 11, 2007 /PRNewswire-FirstCall/ --
Nuvelo, Inc. today announced the publication of data from a studyof NU206 (R-Spondin1), a secreted protein currently in preclinicaldevelopment, showing that it acts as a specific and potentstimulator of gastrointestinal (GI) epithelial cells. Thisepithelial lining is damaged in patients with inflammatory bowelconditions, includin...
Nuvelo Announces Presentation on NU206 at 2007 American Association
for Cancer Research Annual Meeting
SAN CARLOS, Calif., April 04, 2007 /PRNewswire-FirstCall/ --
Nuvelo, Inc. today announced that preclinical data evaluating themechanism of action and role of NU206 (R-Spondin1) as a specificand potent stimulator of the gastrointestinal (GI) epithelial cellswill be presented in an educational session at the 2007 AmericanAssociation for Cancer Research (AACR) Annual Meeting taking placeat t...
More>>